RA Capital Management’s ChemoCentryx, Inc. CCXI Stock Holding History

RA Capital Management’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,155,964	Closed	-$29M	–	110
2022 Q1	$29M	Buy	+1,155,964	New	+$32.5M	0.63%	46
2021 Q4	–	Sell	-218,532	Closed	-$3.74M	–	105
2021 Q3	$3.74M	Sell	218,532 -3,278,107	-94%	-$51.1M	0.05%	92
2021 Q2	$46.8M	Sell	3,496,639 -60,171	-2%	-$1.48M	0.75%	43
2021 Q1	$182M	Sell	3,556,810 -1,219,738	-26%	-$73.4M	2.75%	8
2020 Q4	$296M	Sell	4,776,548 -50,362	-1%	-$2.88M	4.13%	7
2020 Q3	$265M	Hold	4,826,910	–	–	4.84%	3
2020 Q2	$278M	Buy	4,826,910 +650,000	+16%	+$35.4M	5.41%	4
2020 Q1	$168M	Buy	4,176,910 +977,521	+31%	+$41.5M	5.3%	3
2019 Q4	$127M	Buy	+3,199,389	New	+$56.2M	3.84%	5
2013 Q4	–	Sell	-3,045,380	Closed	-$16.9M	–	40
2013 Q3	$16.9M	Buy	+3,045,380	New	+$32.9M	1.77%	18

Other funds holding CCXI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

RA Capital Management's CCXI Position: Q2 2022 in Review

RA Capital Management sold out of ChemoCentryx, Inc. (CCXI) in Q2 2022, closing a stake of 1,155,964 shares — an estimated $29M sold.

RA Capital Management first reported a position in CCXI in Q3 2013 and held it in 10 quarters. The position peaked at $296M in Q4 2020. 182 funds tracked by Wall St. Rank hold CCXI as of Q2 2022.

RA Capital Management reported no remaining ChemoCentryx, Inc. position as of Q2 2022 after selling out during the quarter.
RA Capital Management sold 1,155,964 ChemoCentryx, Inc. shares in Q2 2022, an estimated $29M.
RA Capital Management first reported a position in ChemoCentryx, Inc. in Q3 2013 and held it in 10 quarters.
RA Capital Management's ChemoCentryx, Inc. position peaked at $296M in Q4 2020.
182 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2022.

Based on RA Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.